TOKYO, JAPAN, September 14, 2022 - Heartseed Inc. (Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, is pleased to announce it is the proud recipient of the Most Promising Pipelines - Induced Pluripotent Stem Cell (iPSC) Therapy Award at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022.  The award ceremony was held in conjunction with the 6th Cell & Gene Therapy World Asia 2022 conference on 14th - 15th of September at the Sheraton Tower in Singapore.

HS-001 is an investigational cell therapy using purified cardiomyocytes derived from allogeneic induced pluripotent stem cells (iPSC), which is currently under development for the treatment of advanced heart failure. The award is a testament to the potential and advancement of HS-001, our cardiac remuscularization therapy.

About Heartseed Inc.
Heartseed was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Professor Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo, Japan. Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte-cell product, including purification, cell delivery and iPSC production. Heartseed received "Minister of Science and Technology Policy Award" at Japan Venture Awards 2021 and "Ministry of Education, Culture, Sports, Science and Technology Award" at Academic Startups 2021. For more information, visit heartseed.jp, LinkedIn, YouTube.

About ACGTEA
Asia Pacific CGT Excellence Awards 2022 seeks to give recognition to exceptional Cell & Gene Therapy Pioneers, Researchers, Innovators & Manufacturers that facilitate fast advancement in new therapies, R&D and manufacturing. Featuring top Cell & Gene Therapy leaders in the industry, along with the new cell & gene therapy research development, latest advances and technologies and best practices in Cell & Gene manufacturing, the Asia Pacific CGT Excellence Awards 2022 applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.